H.C. Wainwright Highlight Improved Balance Sheet Supporting Enlivex Ltd. (ENLV) Outlook [Yahoo! Finance]
Enlivex Ltd. - Ordinary Shares (ENLV)
Company Research
Source: Yahoo! Finance
TheFly reported on April 7 that H.C. Wainwright increased its price target on ENLV from $13 to $20 while maintaining a Buy rating. The firm noted that the company has completed its debt financing, which is expected to provide sufficient resources to support the ongoing clinical development of its Allocetra program. On March 23, Enlivex Ltd. (NASDAQ:ENLV) announced that the U.S. Food and Drug Administration cleared its Investigational New Drug application for Allocetra™, an immunotherapy being developed for moderate-to-severe age-related primary knee osteoarthritis. The clearance allows the company to begin a global, randomized, double-blind, placebo-controlled Phase 2b study evaluating intra-articular injections of Allocetra in patients with the condition. H.C. Wainwright Highlight Improved Balance Sheet Supporting Enlivex Ltd. (ENLV) Outlook The trial is designed to assess improvements in pain, physical function, quality of life, and mobility compared with placebo at multiple
Show less
Read more
Impact Snapshot
Event Time:
ENLV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENLV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENLV alerts
High impacting Enlivex Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ENLV
News
- Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee OsteoarthritisGlobeNewswire
- Ondo Global Markets Tokenizes Enlivex’s Ordinary SharesGlobeNewswire
- Enlivex Therapeutics (ENLV) had its price target raised by HC Wainwright from $13.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single PromptGlobeNewswire
- Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48GlobeNewswire
ENLV
Sec Filings
- 4/21/26 - Form 6-K
- 4/8/26 - Form 6-K
- 3/26/26 - Form 6-K
- ENLV's page on the SEC website